Fisher Scientific customers and collaborators can expect the firm to continue to make acquisitions to bolster its life sciences portfolio — particularly its reagent play — as it aims to capitalize on a strong cash position.

Over the past two years, Fisher has entered the RNAi and cell-screening markets through its purchases of Dharmacon and Cellomics, respectively (see BioCommerce Week 8/11/2005).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.